Vollure for the Correction of Atrophic Facial Scarring

NCT ID: NCT04519515

Last Updated: 2022-02-15

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-11
• Study Completion Date: 2023-05-01

Brief Summary

Subjects will be randomized to receive up to 1cc of Juvéderm Vollure on one side of their face and up to 1cc of Saline on the other. On Day 30, this treatment with the same left-right assignment can be repeated. Subjects will return 24-48 hours after their first treatment to fill out questionnaires, take pictures, and to be assessed by blinded evaluators regarding short term adverse events. Subjects will fill out a 30 day subject diary and also return 30 and 90 days after their last treatment to fill out questionnaires, take pictures, complete the Global Aesthetic Improvement Scale (GAIS), and to be assessed on the QGSGS and for long-term adverse events by blinded evaluators. At 12 months, 18 months, and 24 months, the subjects will return to fill out questionnaires, take pictures, and to be assessed by blinded evaluators for long-term efficacy.

Detailed Description

Subjects with grades ranging from 4-55 on the Quantitative Global Scarring Grading System (QGSGS)1 will be randomized to receive up to 1cc of Juvéderm Vollure on one side of their face and up to 1cc of Saline on the other. On Day 30, this treatment with the same left-right assignment can be repeated if optimal correction on the active intervention side has not been achieved according to the treating investigator. Subjects will return 24-48 hours after their first treatment to fill out questionnaires, take pictures, and to be assessed by blinded evaluators regarding short term adverse events. Subjects will fill out a 30 day subject diary and also return 30 and 90 days after their last treatment to fill out questionnaires, take pictures, complete the Global Aesthetic Improvement Scale (GAIS), and to be assessed on the QGSGS and for long-term adverse events by blinded evaluators. The subjects will be eligible to receive treatment with Juvéderm Vollure 90 days after their last treatment on the placebo-controlled side if they choose. In addition, at 12 months, 18 months, and 24 months, the subjects will return to fill out questionnaires, take pictures, and to be assessed by blinded evaluators for long-term efficacy.

Conditions

Atrophic Scar

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Treatment With Juvederm Vollure Right

Injection of Juvederm Vollure on one half of the face, placebo on the other side

Group Type: EXPERIMENTAL

Allergan Vollure

Intervention Type: DEVICE

Injection of Allergan Vollure into Atrophic Scars

Treatment Juvederm Vollure Left

Injection of Juvederm Vollure on one half of the face, placebo on the other side

Group Type: EXPERIMENTAL

Allergan Vollure

Intervention Type: DEVICE

Injection of Allergan Vollure into Atrophic Scars

Interventions

Allergan Vollure

Injection of Allergan Vollure into Atrophic Scars

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• In good general health as evidenced by medical history
• For females of reproductive potential: use of highly effective contraception and a negative urine pregnancy test at screening and all injection visits.
• Score of 4-55 on a validated scarring grading system

Exclusion Criteria

• Subjects with allergies to hyaluronic acid filler, gram positive bacteria or lidocaine.
• Subjects with auto-immune conditions
• Subjects with diabetes
• Subjects with a history of sever anaphylactic reactions
• Subjects with cancer, or other life-threatening medical condition
• Subjects taking anti---coagulants, chemotherapy, immunosuppressive agents, immunomodulatory agents, diuretics, anti---histamines, or anti---inflammatory medications in the 2 weeks prior to the study or who will need to take these medications at any time during the first 120 days of the study.
• Subjects with any scheduled laser, light, or surgical procedures during the study, including dental surgery.
• Subjects who had neuromodulators in the past 6 months or hyaluronic acid fillers in the previous year on the face
• Subjects who at any time had surgery or more permanent fillers in the face such as Bellafill or Radiesse
• Subjects with tattoos or many skin growths on the face that would obscure visualization of the scars
• Subjects with a history of keloid or hypertrophic scar on the face
• Subjects unwilling or unable to sit still while an injector places Juvéderm Vollure in the face
• Subjects unwilling or unable to keep their head still during the photos
• Subjects who are pregnant or nursing
• Female subjects of child-bearing potential unable to take or use some form of birth control
• Subjects with any facial bruising or swelling
• Subjects with current skin infections, tumors, herpes outbreak or dermatitis on the face
• Subjects using skin-irritating topical preparations, pigmenting agents (self-tanning or bleaching creams), in the past two weeks or for the first 120 days of the study on the face
• Any medical condition that in the opinion of the Investigator would make the subject unsuitable for inclusion
• Women who are pregnant or breast feeding, or women of childbearing potential who are not practicing adequate contraception or planning to become pregnant during the study period.
• Study site personnel, close relatives of the study site personnel (e.g. parents, children, siblings, or spouse), employees, or close relatives of employee.

• Minimum Eligible Age: 22 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Allergan

INDUSTRY

Sponsor Role: collaborator

Siperstein Dermatology

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Siperstein Dermatology Group

Boynton Beach, Florida, United States

Countries

United States

Other Identifiers

JVAS002

Identifier Type: -

Identifier Source: org_study_id